p53 Mutation as a genetic trait of typical medullary breast carcinoma

Journal of the National Cancer Institute

Volumn 91, Issue 7, 1999, Pages 641-643

  De Cremoux, Patricia ^a,b   Salomon, Anne Vincent ^b   Liva, Stephane ^b   Dendale, Rémi ^b   Bouchind'homme, Brigitte ^b   Martin, Emmanuel ^b   Sastre Garau, Xavier ^b   Magdelenat, Henri ^b   Fourquet, Alain ^b   Soussi, Thierry ^b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; DIAGNOSTIC VALUE; GENE MUTATION; HUMAN; MEDULLARY CARCINOMA; PRIORITY JOURNAL;

EID: 0033531767     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.7.641     Document Type: Article

References (17)

1. Moore OS, Foste FW. The relatively favorable prognosis of medullary carcinomas of the breast. Cancer 1949;2:635-42.
2. Ridolfi RL, Rosen PP, Port A, Kinne D, Mike V. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977;40:1365-85.
3. Rapin V, Contesso G, Mouriesse H, Bertin F, Lacombe MJ, Piekarski JD, et al. Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer 1988;61:2503-10.
4. Sjogren S, Ignanas M, Holmberg L, Norberg T, Nordgren H, Lindgren A, et al. Re: the p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry - response [letter]. J Natl Cancer Inst 1996;88:1500.
5. Soussi T. The p53 tumor suppressor gene: from molecular biology to clinical investigation. In: Klijn JG, editor. Prognostic and predictive value of p53. Amsterdam (The Netherlands): Elsevier; 1997. p. 3-22.
6. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Borresen AL. Prognostic significance of TP53 alterations in breast carcinoma. Br J Cancer 1993;68:540-8.
7. Flaman JM, Frebourg T, Moreau V, Charbonnier F, Martin C, Chappuis P, et al. A simple p53 functional assay for screening cell lines, blood, and tumors. Proc Natl Acad Sci U S A 1995;92:3963-7.
8. Tenaud C, Negoescu A, Labat-moleur F, Legros Y, Soussi T. Brambilla E. p53 immunolabeling in archival paraffin-embedded tissues: optimal protocol based on microwave heating for eight antibodies on lung carcinomas. Mod Pathol 1994;7:853-9.
9. Rozan S, Vicent-Salomon A, Zafrani B, Validire P, de Cremoux P, Bernoux A, et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer 1998;79:27-33.
10. Domagala W, Harezga B, Szadowska A, Markiewski M, Weber K, Osborn M. Nuclear p53 protein accumulates preferentially in medullary and high-grade ductal but rarely in lobular breast carcinomas. Am J Pathol 1993; 142:669-74.
11. Marchetti A, Buttitta F, Pellegrini S. Campani D, Diella F, Cecchetti D, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993;53: 4665-9.
12. Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis [published erratum appears in Int J Cancer 1996;69:354]. Int J Cancer 1996;69: 135-41.
13. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-10.
14. Eisinger F, Jacquemier J, Charpin C, Stoppa-Lyonnet D, Bressac-de Paillerets B, Peyrat JP, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 1998; 58:1588-92.
15. Crook T, Crossland S, Crompton MR, Osin P, Gusterson BA. p53 mutations in BRCA1-associated familial breast cancer [letter]. Lancet 1997;350:638-9.
16. Bergh J, Norberg T, Sjogren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1: 1029-34.
17. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55:5217-21.